ghadboland,,2019-02-25 15:50:00,418.584,REGN ahhh lost patent
ghadboland,,2019-02-25 15:45:00,416.8,REGN what a drop after positive results Unbelievable
livetraderalerts,,2019-02-25 12:56:00,422.122,REGN 128m ago Positive Results Presented from Two Phase 3 Trials of Dupixent dupilumab in Severe Chronic Rhinosinusit prnewswirecomnewsrelease
EstimizeAlerts,,2019-02-25 12:18:00,423.927,REGN analysts on Estimize are expecting 2441 YoY EPS growth for Q1 down from 3078 in Q4 Reporting 0502 BMOestimizecomintroregncha
EstimizeAlerts,,2019-02-25 12:18:00,423.927,REGNs EYLEA US Product Sales is a key growth metric for their next report on 0502 BMO Will they beat last quarters 1079M EYLEAestimizecomintroregncha
